The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Inhibition of Yes-Associated Protein by Verteporfin Ameliorates Unilateral Ureteral Obstruction-Induced Renal Tubulointerstitial Inflammation and Fibrosis
Open accessAbstract
Yes-associated protein (YAP) activation after acute ischemic kidney injury might be related to interstitial fibrosis and impaired renal tubular regeneration. Verteporfin (VP) is a photosensitizer used in photodynamic therapy to treat age-related macular degeneration. In cancer cells, VP inhibits TEA domain family member (TEAD)-YAP interactions without light stimulation. The protective role of VP in unilateral ureteral obstruction (UUO)-induced renal fibrosis and related mechanisms remains unclear. In this study, we investigate the protective effects of VP on UUO-induced renal tubulointerstitial inflammation and fibrosis and its regulation of the transforming growth factor-β1 (TGF-β1)/Smad signaling pathway. We find that VP decreased the UUO-induced increase in tubular injury, inflammation, and extracellular matrix deposition in mice. VP also decreased myofibroblast activation and proliferation in UUO kidneys and NRK-49F cells by modulating Smad2 and Smad3 phosphorylation. Therefore, YAP inhibition might have beneficial effects on UUO-induced tubulointerstitial inflammation and fibrosis by regulating the TGF-β1/Smad signaling pathway.
Overview
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Verteporfin, a direct inhibitor of YAP-TEAD binding and transcriptional activity, significantly reduced collagen I and fibronectin expression and ameliorated fibrosis severity in a unilateral ureteral obstruction (UUO) kidney fibrosis model, while improving epithelial structural integrity (146, 147).”
From The mechanotransduction-immune axis in organ fibrosis: dual regulatory mechanisms and translational therapeutic perspectives (2025) · doi:10.3389/fimmu.2025.1670213 · cites this paper as [147]
Citations
Cites
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541 · cited 1×
“The infiltration of polymorphonuclear neutrophils and monocytes is characteristic of the initial inflammatory response to injury [28,29].”
BackgroundTGF-β: the master regulator of fibrosis
Meng, X.-M., Nikolic-Paterson, D. J., & Lan, H. Y. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.48 · Cited by 3,528
Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators
Serhan, C. N., Chiang, N., & Van Dyke, T. E. (2008) · Nature Reviews Immunology · doi:10.1038/nri2294 · Cited by 2,932 · cited 1×
“The infiltration of polymorphonuclear neutrophils and monocytes is characteristic of the initial inflammatory response to injury [28,29].”
BackgroundThe Biology of YAP/TAZ: Hippo Signaling and Beyond
Piccolo, S., Dupont, S., & Cordenonsi, M. (2014) · Physiological Reviews · doi:10.1152/physrev.00005.2014 · Cited by 1,802 · cited 2×
“YAP is related to nephron morphogenesis, and TAZ inactivation causes polycystic kidney disease [14].”
BackgroundMechanisms of Hippo pathway regulation
Meng, Z., Moroishi, T., & Guan, K.-L. (2016) · Genes & Development · doi:10.1101/gad.274027.115 · Cited by 1,667 · cited 12×
“Once the Hippo pathway has been activated, it limits tissue growth and cell proliferation through the phosphorylation and degradation of YAP/TAZ.”
BackgroundInfluentialLiu-Chittenden, Y., Huang, B., Shim, J. S., Chen, Q., Lee, S.-J., Anders, R. A., Liu, J. O., & Pan, D. (2012) · Genes & Development · doi:10.1101/gad.192856.112 · Cited by 1,452 · cited 1×
“showed that VP inhibits TEA domain family member (TEAD)–YAP interactions in cancer cells without light stimulation [16].”
BackgroundThe Hippo Pathway: Biology and Pathophysiology
Ma, S., Meng, Z., Chen, R., & Guan, K.-L. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-013118-111829 · Cited by 1,387 · cited 2×
“In contrast, when the Hippo pathway is turned off, YAP/TAZ is dephosphorylated and translocated into the nucleus to induce target gene transcription [12,13].”
BackgroundThe Hippo–YAP pathway in organ size control and tumorigenesis: an updated version
Zhao, B., Li, L., Lei, Q., & Guan, K.-L. (2010) · Genes & Development · doi:10.1101/gad.1909210 · Cited by 1,144
Chapter 1: Definition and classification of CKD
(2013) · Kidney International Supplements · doi:10.1038/kisup.2012.64 · Cited by 1,110
Cited by
The Hippo signalling pathway and its implications in human health and diseases
Fu, M., Hu, Y., Lan, T., Guan, K.-L., Luo, T., & Luo, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01191-9 · Cited by 742
Epithelial–mesenchymal transition in tissue repair and degeneration
Youssef, K. K., & Nieto, M. A. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00733-z · Cited by 159
“Verteporfin, a drug that blocks the interaction between YAP/TAZ and their effector TEAD, reduces TGFβ–SMAD signalling, decreases inflammation and myofibroblast activation in a model of murine renal fibrosis 220 (Fig.”
YAP/TAZ: Molecular pathway and disease therapy
Wei, Y., Hui, V. L. Z., Chen, Y., Han, R., Han, X., & Guo, Y. (2023) · MedComm · doi:10.1002/mco2.340 · Cited by 122
Yeh, T.-H., Tu, K.-C., Wang, H., & Chen, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031755 · Cited by 119
“…of 22 Another compound, Vertepor fi n (VP), a photosensitizer used in treating age-related macular degeneration, can bind to YAP, disrupting its interaction with TEAD, which might improve renal tubulointerstitial in fl ammation and fi brosis [139,140]. modulation of the Hippo signaling pathway [138].”
BackgroundDecellularized Disc Hydrogels for hBMSCs tissue-specific differentiation and tissue regeneration
Peng, Y., Qing, X., Lin, H., Huang, D., Li, J., Tian, S., Liu, S., Lv, X., Ma, K., Li, R., et al. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.03.014 · Cited by 90
Metadata
- Authors
- Jin, J., Wang, T., Park, W., Li, W., Kim, W., Park, S. K., & Kang, K. P.
- Affiliations
- Jeonbuk National University Hospital (KR)
- Corresponding author
- Park, Sung Kwang
- Kang, Kyung Pyo
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-10-31
- Volume
- 21
- Issue
- 21
- Pages
- 8184
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7662854
- OpenAlex
- W3095066918
- Cited by
- 43
- References
- 44
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 7 · 2023: 8 · 2022: 8 · 2021: 5 · 2020: 1
- FWCI
- 2.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Research Foundation of Korea (NRF-2018R1D1A1B07045790, NRF- 2017R1D1A3B03035494)
- Fund of Biomedical Research Institute, Jeonbuk National University Hospital (CUH2020-0014)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- verteporfin, YAP, unilateral ureteral obstruction, tubulointerstitial fibrosis, tubulointerstitial inflammation, TGF-β1/Smad signaling, myofibroblast activation, extracellular matrix deposition, acute kidney injury, kidney regeneration
- MeSH terms
- Verteporfin, YAP-Signaling Proteins, Animals, Cells, Cultured, Disease Models, Animal, Fibrosis, Inflammation, Kidney Diseases, Male, Mice, Inbred C57BL, Ureteral Obstruction, Photosensitizing Agents, Cell Cycle Proteins, Adaptor Proteins, Signal Transducing, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of Yes-Associated Protein by Verteporfin Ameliorates Unilateral Ureteral Obstruction-Induced Renal Tubulointerstitial Inflammation and Fibrosis. https://app.cochat.ai/papers/10.3390/ijms21218184
- The paper
- Jin, J., Wang, T., Park, W., Li, W., Kim, W., Park, S. K., & Kang, K. P. (2020). Inhibition of Yes-Associated Protein by Verteporfin Ameliorates Unilateral Ureteral Obstruction-Induced Renal Tubulointerstitial Inflammation and Fibrosis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms21218184
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.